Abstract
BackgroundCanakinumab is a fully human, selective, anti-IL-1β monoclonal antibody approved for the treatment of patients with systemic juvenile idiopathic arthritis (SJIA). In the phase III trials, macrophage activation syndrome (MAS),...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have